Aminophylline increases cerebral metabolic rate and decreases anoxic survival in young mice.
In weanling mice treated with pharmacologic doses of aminophylline, the concentrations of adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate in the brain increased 44 and 36 percent, respectively, and the cerebral metabolic rate was three times that in controls. In neonatal mice, therapeutic doses of aminophylline greatly decreased the rate of anoxic survival in vivo and the duration of gasping of the isolated head. The findings suggest caution in the use of this drug and other methylxanthines in hypoxic human newborns.
D000227:Adenine Nucleotides / Q000378:metabolism; D000628:Aminophylline / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D001049:Apnea / Q000188:drug therapy; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D002639:Cheyne-Stokes Respiration / Q000188:drug therapy; D000242:Cyclic AMP / Q000378:metabolism; D004734:Energy Metabolism / Q000187:drug effects*; D005947:Glucose / Q000378:metabolism; D005958:Glucosephosphates / Q000378:metabolism; D006801:Humans; D000860:Hypoxia / Q000503:physiopathology; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy; D051379:Mice
D000227:Adenine Nucleotides; D005958:Glucosephosphates; D000628:Aminophylline; D000242:Cyclic AMP; D005947:Glucose